Präventive Magenchirurgie bei hereditärem Magenkarzinom und genetischer Prädisposition

Zusammenfassung

Das hereditäre diffuse Magenkarzinom (HDGC) infolge krankheitsverursachender Varianten in CDH1 oder CTNNA1 sowie die familiäre adenomatöse Polyposis (FAP, krankheitsverursachende Varianten in APC) erfordern individuelle Strategien zur Krebsprävention. Beim HDGC wird eine prophylaktische totale Gastrektomie empfohlen, während bei FAP-Patienten die endoskopische Überwachung mit Interventionen im Vordergrund steht. Die Wahl der Rekonstruktion (Roux-en-Y, Jejunuminterposition, Double-Tract) beeinflusst sowohl die Möglichkeit zur endoskopischen Überwachung des Duodenums als auch die Lebensqualität. Entscheidungen über Überwachung vs. Operation sollten patientenbezogen unter Abwägung von Krebsrisiko und postoperativer Lebensqualität erfolgen.

Abstract

Hereditary diffuse gastric cancer (HDGC) caused by disease-causing variant in CDH1 or CTNNA1 and familial adenomatous polyposis (FAP, disease-causing variants in APC) require individualised cancer prevention strategies. In HDGC, prophylactic total gastrectomy is often recommended, whereas in FAP, endoscopic surveillance with interventions plays a central role. The choice of reconstruction (Roux-en-Y, jejunal interposition, double-tract) affects both duodenal accessibility and quality of life. Decisions between surveillance and surgery should be made individually, balancing cancer risk and postoperative quality of life.

Schlüsselwörter

Magenkarzinom - prophylaktische Gastrektomie - hereditäres Magenkarzinom - FAP - CDH1

Keywords

gastric cancer - preventive gastrectomy - hereditary gastric cancer - FAP - CDH1

Publikationsverlauf

Eingereicht: 22. September 2025

Angenommen: 23. Oktober 2025

Artikel online veröffentlicht:
26. November 2025

• Literatur

• 1 Mokhtari-Esbuie F, Szeglin B, Ravari MR. et al. Pioneering use of genetic analysis for CDH1 to identify candidates for prophylactic total gastrectomy to prevent hereditary diffuse gastric cancer. eGastroenterology 2023; 1: e100017
• 2 Gullo I, Grillo F, Mastracci L. et al. Precancerous lesions of the stomach, gastric cancer and hereditary gastric cancer syndromes. Pathologica 2020; 112: 166-185
• 3 Blair VR, McLeod M, Carneiro F. et al. Hereditary diffuse gastric cancer: updated clinical practice guidelines. Lancet Oncol 2020; 21: e386-e397
• 4 Zaffaroni G, Mannucci A, Koskenvuo L. et al. Updated European guidelines for clinical management of familial adenomatous polyposis (FAP), MUTYH-associated polyposis (MAP), gastric adenocarcinoma, proximal polyposis of the stomach (GAPPS) and other rare adenomatous polyposis syndromes: a joint EHTG-ESCP revision. Br J Surg 2024; 111: znae070
• 5 Binachi LK, Burke CA, Bennett AE. et al. Fundic gland polyp dysplasie is commin in familial adenomatous poylposis. Clin Gastroenterolo Hepatol 2008; 6: 180-185
• 6 Mankaney G, Leone P, Cruise M. et al. Gastric cancer in FAP: a concerning rise in incidence. Fam Cancer 2017; 16: 371-376
• 7 Ganschow P, Trauth S, Hinz U. et al. Risk Factors Associated With Pouch Adenomas in Patients With Familial Adenomatous Polyposis. Dis Colon Rectum 2018; 61: 1096-1101
• 8 Carneiro F. Familial and hereditary gastric cancer, an overview. Best Pract Res Clin Gastroenterol 2022; 5859: 101800
• 9 Carvalho J, Oliveira P, Senz J. et al. Redefinition of familial intestinal gastric cancer: clinical and genetic perspectives. J Med Genet 2021; 58: 1-11
• 10 Pandalai PK, Lauwers GY, Chung DC. et al. Prophylactic total gastrectomy for individuals with germline CDH1 mutation. Surgery 2011; 149: 347-355
• 11 Davis JL, Strong VE. Controversies and strengths in prophylactic total gastrectomy for germline CDH1 pathogenic variant carriers. Eur J Cancer Prev 2023; 32: 308-309
• 12 Lerner BA, Gupta S, Burke CA. et al. Advancing the Evaluation and Management of CDH1-Associated Gastric Cancer. J Natl Compr Canc Netw 2025; 23: e257006
• 13 Zare B, Monahan KJ. Guidelines for Familial Adenomatous Polyposis (FAP): challenges in defining clinical management for a rare disease. Fam Cancer 2025; 24: 35
• 14 Vos EL, Salo-Mullen EE, Tang LH. et al. Indications for Total Gastrectomy in CDH1 Mutation Carriers and Outcomes of Risk-Reducing Minimally Invasive and Open Gastrectomies. JAMA Surg 2020; 155: 1050-1057
• 15 Pantelis D, Lingohr P, Hueneburg R. et al. Outcomes after Prophylactic Total Gastrectomy for Hereditary Diffuse Gastric Cancer. Zentralbl Chir 2020; 145: 41-47
• 16 Li ZY, Zhou YB, Li TY. et al. Robotic Gastrectomy Versus Laparoscopic Gastrectomy for Gastric Cancer: A Multicenter Cohort Study of 5402 Patients in China. Ann Surg 2023; 277: e87-e95
• 17 Syn NL, Wee I, Shabbir A. et al. Pouch Versus No Pouch Following Total Gastrectomy: Meta-analysis of Randomized and Non-randomized Studies. Ann Surg 2019; 269: 1041-1053
• 18 Shah RS, Mehta N, Mankaney G. et al. Endoscopic Surveillance of Duodenal Polyposis After Total Gastrectomy in Familial Adenomatous Polyposis. ACG Case Rep J 2020; 7: e00445
• 19 Zuin M, Celotto F, Pucciarelli S. et al. Isoperistaltic Jejunal Loop Interposition after Total Gastrectomy for Gastric Cancer in Patients with Familial Adenomatous Polyposis. J Gastric Cancer 2020; 20: 225-231
• 20 Srinivasa D, Wray CJ. Total gastrectomy with isoperistaltic jejunal interposition flap for symptomatic management of gastric polyposis from familial adenomatous polyposis. J Gastrointest Oncol 2014; 5: E18-E21
• 21 Barbosa J, Lopes V, Sousa F. et al. Jejunal flap interposition after total gastrectomy in managing patients with familial adenomatous polyposis: A report on the experience of a single centre. J Minim Access Surg 2025; 21: 7-10
• 22 Stillman MD, Kusche N, Toledano S. et al. Short and long-term outcomes of prophylactic total gastrectomy in 54 consecutive individuals with germline pathogenic mutations in the CDH1 gene. J Surg Oncol 2022; 126: 1413-1422
• 23 Zittel TT, Maier GW, Starlinger M. et al. Kalzium and bone metabolism after gastrectomy. Chirurg 1997; 68: 784-788
• 24 Oh HJ, Yoon BH, Ha YC. et al. The change of bone mineral density and bone metabolism after gastrectomy for gastric cancer: a meta-analysis. Osteoporos Int 2020; 31: 267-275
• 25 Mine S, Sano T, Tsutsumi K. et al. Large-scale investigation into dumping syndrome after gastrectomy for gastric cancer. J Am Coll Surg 2010; 211: 628-636
• 26 Realis Luc M, Bonomi AM, Carbone F. et al. Roux-en-Y with or without jejunal J-pouch reconstruction after total gastrectomy for gastric cancer: systematic review and meta-analysis of long-term functional outcomes. J Gastrointest Surg 2024; 28: 291-300
• 27 Rosania R, Chiapponi C, Malfertheiner P. et al. Nutrition in Patients with Gastric Cancer: An Update. Gastrointest Tumors 2016; 2: 178-187
• 28 Forrester JD, Foster D, Ford JM. et al. Surgery for Hereditary Diffuse Gastric Cancer: Long-Term Outcomes. Cancers (Basel) 2022; 14: 728
• 29 Muir J, Aronson M, Esplen MJ. et al. Prophylactic Total Gastrectomy: a Prospective Cohort Study of Long-Term Impact on Quality of Life. J Gastrointest Surg 2016; 20: 1950-1958
• 30 Worster E, Liu X, Richardson S. et al. The impact of prophylactic total gastrectomy on health-related quality of life: a prospective cohort study. Ann Surg 2014; 260: 87-93
• 31 Lim HJ, di Pietro M, O’Neill JR. A Systematic Review on Clinical and Health-Related Quality of Life Outcomes following Total Gastrectomy in Patients with Hereditary Diffuse Gastric Cancer. Cancers (Basel) 2024; 16: 473
• 32 Roberts G, Hardwick R, Fitzgerald RC. Decision making, quality of life and prophylactic gastrectomy in carriers of pathogenic CDH1 mutations. Transl Gastroenterol Hepatol 2017; 2: 21